Juica-Avello S.Riquelme-Vergara C.Condeza-Riquelme F.González-Burboa A.Fuentealba-Sandoval M.Klaassen-Pinto G.Pérez-Villalobos C.Vera-Calzaretta A.Contreras-Espinoza L.Werlinger-Estay E.Herrera-Hormazábal C.2025-03-142025-03-142022https://hdl.handle.net/20.500.12740/17176Aim. The aim of this study was to evaluate the efficacy and safety of tiapride compared to topiramate as a prophylactic in chronic migraine. Patients and methods. The study was conducted under randomised and double blind conditions. A total of 56 patients aged 18-65 years with chronic migraine were assigned to two treatment arms: tiapride, 100 mg twice daily, or topiramate, 25 mg twice daily, for 12 weeks. The primary endpoint was the change in the monthly average number of migraine days. In addition, measurements were performed to determine the change in the monthly number of headache days, the percentage of subjects with >50% and >75% decrease in their monthly migraine days, and the change in headache impact as measured by the Headache Impact Test-6. Results. The intention-to-treat population included 39 subjects (tiapride = 21; topiramate = 18), 35 of whom (tiapride = 18; topiramate = 16) completed the trial. The tiapride group had a mean reduction of 7.2 ± 7.5 migraine days per month compared to 7.6 ± 5.8 for the topiramate group (p = 0.86). As with the other efficacy variables measured, no differences were found between the two groups. Adverse side effects were mild in both groups. Conclusion. In patients with chronic migraine, tiapride was found to be an effective, safe and well-tolerated prophylactic treatment when compared to topiramate. © 2022 Revista de Neurologia. All rights reserved.PDFChronic migraineHeadacheMigraine prophylaxisMigraine treatmentTiaprideTopiramateArtículohttp://dx.doi.org/10.33588/rn.7410.2021325